Loading...

Home
Stock
CYTK

CYTK News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CYTK News

Cytokinetics Closes $805 Million Public Offering

2d agoNewsfilter

Cytokinetics Raises $700M in Upsized Public Offering

3d agoseekingalpha

Cytokinetics Prices $700 Million Public Offering at $71 per Share

3d agoNewsfilter

CYTOKINETICS INC: B. RILEY INCREASES TARGET PRICE FROM $108.00 TO $146.00

Cytokinetics Reports Strong Q1 2026 Earnings with MYQORZO Launch Success

4d agoseekingalpha

Cytokinetics (CYTK) Q1 2026 Earnings Transcript

5d agoNASDAQ.COM

Cytokinetics Inc. Announces $650 Million Common Stock Offering in SEC Filing

Rockwell Automation Surges on Strong Q2 Earnings Beat

CYTK Events

Deal Size Increased to $700M

The deal size was increased to $700M in common stock from $650M in common stock. Morgan Stanley, Goldman Sachs, JPMorgan and Jefferies acted as joint book running managers for the offering.

CYTK Monitor News

Cytokinetics Presents MYQORZO Research at Heart Failure Congress

Cytokinetics Presents MYQORZO Research at Heart Failure Congress

Cytokinetics Executive's Stock Sale Raises Concerns

Cytokinetics Faces Challenges Despite FDA Approval of MYQORZO

Cytokinetics to Announce Q4 Earnings Amid FDA Approval for Aficamten

Cytokinetics stock rises amid sector rotation despite shareholder investigation

Cytokinetics Receives FDA Approval for MYQORZO, Driving Stock Surge

Cytokinetics faces shareholder investigation amid FDA review delay

CYTK Earnings Analysis

Cytokinetics Earnings Report: Key Highlights & Forecast- Intellectia AI™

Cytokinetics Q4 2024: Earnings Growth & Strategic Milestones- Intellectia AI™

People Also Watch